GLP-1 Users Are Cutting Grocery Spend by 5.3% — The Food Industry's Reformulation Has Begun

A 2025 IQVIA/Numerator consumer spending analysis found that households with at least one GLP-1 user reduced grocery spending by an average of 5.3% compared to matched control households. The reduction was concentrated in categories associated with high-caloric density and low nutritional value: sugary beverages, snack foods, ultra-processed convenience items. GLP-1 users were spending more, as a fraction of reduced total grocery budgets, on protein-dense and nutrient-dense foods.

The 5.3% figure is deceptively small. GLP-1 prescriptions in the United States exceeded 9 million active users as of Q4 2025, with projections suggesting 30-50 million US users within five years if cost and supply barriers are reduced. A 5.3% grocery spending reduction across 30-50 million users represents a structural demand shock to the food industry measured in tens of billions of dollars annually — concentrated in the categories that currently generate the highest margins.

The food industry is beginning to respond. The signal is not yet visible in reformulated products on shelves. It is visible in the strategy documents, the consultant briefings, and the R&D pipeline announcements that precede reformulation by two to three years.

The Signal

Nestlé CEO Mark Schneider, speaking at a February 2026 investor conference, stated explicitly that the company was "closely monitoring" GLP-1 drug adoption and had begun R&D work on formulations optimized for users with reduced appetite. This is the first major food company CEO to publicly acknowledge GLP-1 as a strategic planning variable — a signal that the industry has moved from dismissing the trend to building it into long-range planning.

The Wall Street Journal reported in March 2026 that at least three major US food manufacturers — not named in the report — had established internal working groups on GLP-1 consumer behavior, with mandates to identify product reformulation priorities and potential new product categories that would capture the GLP-1 consumer's shifted preferences.

The investment community has already priced in a version of this signal. Between January 2024 and January 2026, the market capitalizations of the major carbonated beverage companies (Coca-Cola, PepsiCo), the major snack companies (Mondelez, Kellanova), and the major fast food chains (McDonald's, Yum! Brands) underperformed the S&P 500 by an average of 12 percentage points. The market is pricing a demand reduction that is not yet fully visible in reported sales data — because the GLP-1 user base, while growing, is still a small fraction of total food consumers.

The Historical Context

The food industry's response to demand shocks driven by health consciousness has a consistent historical pattern: initial denial, followed by reluctant adaptation, followed by eventual embrace once the adaptation becomes profitable.

The fat reduction cycle of the 1980s-1990s is the relevant precedent. When dietary fat was identified as a health risk (incorrectly, as subsequent research established) and consumer demand shifted toward low-fat products, food manufacturers initially resisted reformulation, arguing that fat was necessary for flavor and texture. The resistance lasted until the market made adaptation economically necessary — at which point the food industry reformulated aggressively, producing the low-fat product proliferation of the 1990s. The reformulations were commercially successful even as they were nutritionally mixed: replacing fat with sugar to maintain palatability produced products that were technically low-fat but not demonstrably healthier.

The GLP-1 shift is structurally different from the fat reduction cycle in one critical dimension: the driver is biological rather than attitudinal. Low-fat consumption was a choice made by health-conscious consumers who could revert to full-fat products at any time. GLP-1 use reduces the neurological reward signal from high-caloric food — users report not just reduced appetite but reduced craving for the specific flavor profiles (sweet, salty, fatty, high-caloric) that the food industry's product development has been optimized to trigger. The demand shift is not attitudinal; it is pharmacological. It will not reverse if the product reformulation is inadequate.

The Mechanism

The GLP-1 demand shift is hitting the food industry through three distinct channels.

Volume reduction in high-margin categories: The categories most affected — carbonated beverages, snack foods, confectionery, fast food — are among the highest-margin categories in the consumer packaged goods industry. Volume reductions in these categories produce disproportionate earnings impact relative to volume because margins are high. The 5.3% grocery spending reduction concentrated in these categories is hitting operating income harder than equivalent reductions in lower-margin categories would.

Preference shift toward protein: GLP-1 users consistently report increased relative preference for protein-dense foods — the satiety signal that GLP-1 enhances is more responsive to protein than to carbohydrate. This creates a structural demand shift toward protein categories (meat, dairy, eggs, legumes, protein supplements) and away from carbohydrate-dominant snack and beverage categories. The protein opportunity is real, but the protein supply chain is structured differently from the snack supply chain — the adaptation requires investment in different raw material relationships, different manufacturing infrastructure, and different retail positioning.

Portion size reduction across all categories: GLP-1 users consume smaller portions of every food category, not just the high-caloric ones. This creates pressure on the portion-size inflation that has characterized food product development for three decades — larger portions at marginal cost increases were the primary driver of caloric increase in the American diet, and they were highly profitable. GLP-1 users buying half-sized portions, or leaving food on their plates, represent a structural shift in the unit economics of food manufacturing and food service.

Second-Order Effects

The agricultural implications are significant and underanalyzed. If GLP-1 adoption reduces total caloric consumption by 10-15% across 30-50 million US users, the aggregate caloric demand reduction has implications for agricultural production — specifically for the corn and soy supply chains that underpin the ultra-processed food and livestock feed industries. A sustained reduction in demand for ultra-processed calories would eventually propagate to reduced demand for the commodity inputs that produce those calories.

The restaurant industry impact is immediate and measurable. Fast food companies — whose business models depend on high-frequency, high-caloric purchases — are the first to show demand pressure from GLP-1 adoption. McDonald's Q4 2025 earnings cited consumer health consciousness as a headwind, and while the company did not specifically attribute the headwind to GLP-1, the demographic correlation is visible in the data.

The obesity-healthcare cost intersection creates a second-order policy signal. If GLP-1 drugs reduce obesity prevalence significantly — and the clinical data suggests they do when adherence is maintained — the downstream reduction in obesity-related healthcare costs (diabetes, cardiovascular disease, joint replacement, sleep apnea) could be measured in hundreds of billions of dollars over a decade. This creates a fiscal argument for GLP-1 drug coverage expansion by Medicare and Medicaid that is currently being weighed against the drugs' high list prices.

What to Watch

Nielsen/Circana category volume data: Monthly consumer packaged goods volume data by category is the leading indicator of the GLP-1 demand shift. Watch for sustained volume declines in carbonated beverages, salty snacks, and confectionery that exceed the broader consumer spending environment.

Food manufacturer R&D announcements: Watch for product launches explicitly targeting GLP-1 users — high-protein, nutrient-dense, smaller-portion products. The first major food company to successfully market to GLP-1 users as a distinct consumer segment will establish the template for the industry's adaptation.

GLP-1 prescription volume and coverage expansion: The demand shift scales with GLP-1 adoption. Watch for Medicare/Medicaid coverage announcements and any reduction in list prices through negotiation or competition that would accelerate adoption.